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INVESTIGATING THE RESPONSE OF OLIGODENDROCYTE PROGENITOR
CELLS TO THE CUPRIZONE MODEL OF DEMYELINATION
By David Thomas Moffatt, B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Raymond J. Colello
Assistant Professor, Anatomy and Neurobiology

Multiple sclerosis and other myelin diseases affect the quality of life many people. In the
United States alone, multiple sclerosis afflicts as many as 400,000 individuals. Myelin,
which is attacked by multiple sclerosis, plays a critical role in maintaining the healthy
function of the adult nervous system. There are many model systems that study myelin
and its formation and loss. Our lab investigates the cuprizone model of demyelination and
remyelination. The cuprizone model is commonly believed only to affect adult
oligodendrocytes, which it kills. The current study investigates whether other cells in the
oligodendrocyte line, such as oligodendrocyte progenitor cells, might also be susceptible to
xi

xii
the toxic effects of cuprizone. Oligodendrocyte progenitor cells may play an important
role in repairing and replacing myelin after demyelinating insults. So any effect that the
model has on these cells may be relevant to the use of the model for studying
remyelination. In order to evaluate the potential effects of cuprizone, dividing cells in adult
mice were labeled with the proliferation marker, Bromodeoxyuridine (BrdU).
Immunohistochemical labeling of BrdU shows that the number of actively dividing cells
seen in the subventricular and subgranular zones sharply and dramatically decreases after
just 1 week on cuprizone. In the following weeks, the number of dividing cells increases,
but even after 3 weeks of recovery without cuprizone, the number of BrdU+ cells does not
return to control levels. These results may have significant ramifications in the
interpretation of results obtained from the cuprizone model, and this finding must be
considered in selecting a model for future demyelination studies.

1
The Significance and Modeling of Demyelination and Remyelination

The role of the nervous system can be simplified to sending, receiving, and integrating
signals. As these functions do not necessarily occur in the same place in the nervous system
or even in the same parts of a given cell, the successful and reliable conduction of signals
from one place to another is of critical importance to the function of the entire nervous
system. In many cases, the conduction of action potentials (APs) is critically dependent on
the presence of a healthy sheath of myelin enveloping the axon. The myelin sheaths along an
axon enable the high transmission speeds nerves need for efficient communication. In the
central nervous system, (CNS) the production and maintenance of myelin is the responsibility
of cells called oligodendrocytes. Without normal myelination and healthy oligodendrocytes,
AP conduction becomes slow and inconsistent, causing myriad neurological symptoms. In
addition, axons can become damaged in the absence of myelin (Ferguson et al., 1997).
The significance of myelin is highlighted by the severity of myelin disorders. In
order to study demyelinating diseases like multiple sclerosis (MS), many model systems have
been developed. Several therapeutic approaches to myelination problems can be tested on
these models. Since myelin problems are necessarily oligodendrocyte problems, therapies
focusing on these cells are promising. Damaged or dead oligodendrocytes can be replaced
either by promoting the growth and differentiation of endogenous oligodendrocyte progenitor
cells (OPCs), or by directly injecting either OPCs or immature oligodendrocytes into the
damaged CNS (Blakemore and Irvine, 2008).
1
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It was during the study of the remyelinating capacity of endogenous stem cell
populations in a cuprizone model of demyelination that the idea for the present study arose.
Cuprizone is one of several toxin-based methods for inducing and studying demyelination. It
is theorized that cuprizone selectively kills oligodendrocytes because of their high metabolic
demand (Matsushima and Morell, 2001). We hypothesized that, if oligodendrocytes have a
susceptibility to the toxin because of their energy demand, then developing oligodendrocytes
would also be vulnerable because, in addition to being in the oligodendrocyte lineage, their
metabolism is taxed by growing, dividing, developing, and migrating. We proceeded to
investigate the oligodendrocyte precursor populations to determine their response to a
demyelinating regimen of cuprizone.
In order to realize the relevance of this idea, an understanding of myelin and its
function and formation is necessary. Consequently, in this thesis, I shall describe the
importance of OPC populations in remyelinating the adult CNS. This requires a discussion
of myelin and the cells associated with it. The nature of demyelination and remyelination as
well as the models for studying myelin pathologies will also be introduced because myelin
diseases represent a major class of neurological disorders.
1.1 Myelin Structure and Function in the CNS
Myelin is a specialized cell membrane that is wrapped around axons in many closely
apposed lamellae forming a structure called the myelin sheath. Myelin is literally an
extension of the cell membrane of the myelinating cell, either a Schwann cell in the peripheral
nervous system or an oligodendrocyte in the CNS. Unusual for a cell membrane, the dry
weight of myelin is composed of a ratio of 70% lipid to 30% proteins, whereas most cell
membranes are higher in proteins than in lipids (Baumann and Pham-Dinh, 2001). Also,
because of its tightly wrapped configuration, there is very little cytosol and water associated
with myelin (Bunge, 1968).
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Along the length of a given axon, myelin sheaths are arranged segmentally, with short
exposed regions between them. These regions between myelin segments are called Nodes of
Ranvier (Bunge, 1968) (see Figure 1). In the peripheral nervous system, usually only one
segment is associated with one Schwann cell, but in the CNS, several myelin segments on
many axons can be continuous with a single oligodendrocyte. Oligodendrocytes have been
known to myelinate up to 50 axon segments with the unfortunate corollary that killing one
oligodendrocyte can cause widespread effects (Baumann and Pham-Dinh 2001). In 1928, Pio
del Rio Hortega characterized the oligodendrocyte as the cell responsible for myelination in
the CNS, but the physiological function of myelin was not determined until 20 years later
(Huxley and Stampfli, 1949).
In most vertebrates, myelination is necessary for attaining the impulse conduction
velocities required for a nervous system to be useful. Without myelin, nature’s best means of
increasing conduction velocity is to increase axonal caliber. Cable theory predicts that
increasing diameter reduces resistance and increases velocity (Shepherd, 1994). In order to
achieve usefully short times from stimulus to perception to response, very large axons would
be required. Anatomical restrictions make this unfeasible.
With myelination, the neuron achieves high speeds without unreasonably increasing
the diameter. In a myelinated neuron, electrically insulating myelin is wrapped several times
around the axon, drastically increasing resistance and decreasing capacitance across the
axonal cell membrane. The result of this is that current in the cytoplasm flows rapidly down
the axon to the next node instead of flowing across the axolemma as it does along a naked
axon (Shepherd, 1994). In this case, the transmembrane currents that are the action potential
appear to jump down the axon, skipping internodes. This
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Figure 1. Oligodendrocyte and Myelin Structure and Organization.
An oligodendrocyte (O) can have many processes which wrap axons in multilayered
sheaths of myelin (M). The myelin-wrapped portion of an axon is termed the internode (I)
while the exposed axon is called the node of Ranvier (N). To achieve high signal
conduction velocities, action potentials jump from node to node across internodes in a
process called saltatory conduction. A single oligodendrocyte may ensheath as many as 50
axonal segments. (modified with permission from Baumann, 2001).
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Figure 1. Oligodendrocyte and Myelin Structure and Organization.

6
saltatory conduction, in which action potentials jump quickly from one node to the next, is the
key to achieving high conduction velocities (Stampfli, 1954). Since myelin makes such a
significant contribution to nerve impulse conduction, it is worth looking at the cells producing
it.
1.2 Oligodendrocytes and their Origins:
The myelinating oligodendrocyte is the end product of a series of maturational
progressions. Multipotential neural stem cells, properly guided by molecular cues, can
develop into oligodendrocytes (Nait-Oumesmar et al., 2007). Neural stem cells differentiate
into early oligodendrocyte progenitor cells with migratory capacity. The cells then progress
through early and late progenitor stages at which point their fate is already determined; late
OPCs can remain undifferentiated as adult progenitor cells, or they can further differentiate
into premyelinating oligodendrocytes. If needed, the premyelinating cells mature into
myelinating oligodendrocytes; otherwise, they may undergo apoptosis (Barres, 1992; Trapp
et al., 1997). The stages of oligodendrocyte lineage can be loosely defined morphologically
or by the unique sets of proteins they express, although precise discrimination among cells in
the oligodendrocyte lineage is difficult (Trapp et al., 2004) (Figure 2).
1.21 OPC Populations in the Adult CNS
Since MS rarely affects the very young, developing brain, demyelination and
remyelination usually involve mature oligodendrocytes and adult progenitors (Wood and
Bunge, 1991). Because of this, the oligodendrocyte lineage and the sources of early OPCs in
the adult are critical to remyelination. There are several potential populations of early OPCs
in the adult brain: The subventricular zone (SVZ), the subgranular zone (SGZ) of the dentate
gyrus in the hippocampus, and the white-matter tracts such as the corpus callosum (CC)
(Nait-Oumesmar et al., 1999; Palmer et al., 1997; Chang et al., 2004). The OPC populations
in the SVZ and white matter are well documented, and neural stem cells from the SGZ are a
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potential source of oligodendrocytes because they have been shown to differentiate into
oligodendrocytes in vitro (Doetsch et al, 1997; Gensert and Goldman, 1996; Palmer et al.,
1997) (Figure 3).
The SVZ is located in the lateral walls of the lateral ventricles and is well known for
being a significant site of neurogenesis and gliogenesis during development. The SVZ retains
these properties into adulthood (Doetsch et al., 1997, Paterson et al., 73). A histological
study of the SVZ found that, excluding the ependymal cells lining the ventricles, as many as
15% of the cells in the SVZ of rats are putative precursor cells (Doetsch et al., 1997). It has
also been established that that SVZ precursors respond to demyelination by dividing,
migrating, and maturing into oligodendrocytes (Nait-Oumesmar et al, 1999).
The corpus callosum and some other subcortical white matter also contain cells
capable of differentiating into myelinating oligodendrocytes (Gensert and Goldman,
1996). There is also a thin, expansive, germinal layer just deep to the caudal aspect of the
corpus callosum (Seri et al., 2006). In development, migrating OPCs move into the white
matter tracts, and, if they do not die or develop into mature oligodendrocytes, enter a quiescent
state as adult progenitors (Levine et al., 2001). These cells can be likened to satellite cells in
muscle in that they have been shown to respond to myelin damage and mature into
myelinating cells.
The remaining candidate pool of remyelinating cells lies in the hippocampus. The
subgranular zone of the dentate gyrus is a site of adult neurogenesis (Kempermann, 1997).
Additionally, investigation has shown that the SGZ cells producing neurons are multipotential
stem cells. That same study showed that the SGZ derived stem cells can be induced in vitro
to differentiate into glia (Palmer et al, 1997). For this reason, the SGZ is treated here as a
population with the potential to remyelinate.

8

Figure 2. Oligodendrocyte Lineage
Oligodendrocyte progenitor cells in the adult arise from generative zones in the
brain such as the subventricular zone (SVZ). These early progenitors can migrate
throughout the CNS and differentiate into either myelinating oligodendrocytes or
quiescent adult progenitor cells. (Adapted from Trapp et al., 2004).
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Figure 2. Oligodendrocyte Lineage
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Figure 3. Proliferative Zones of the Adult Mouse Brain
These sagittal and coronal mouse brain sections highlight the regions of interest to
the present study. In the nissl-stained sagittal section, A, the corpus callosum is
shown in green, the SVZ in blue, and the SGZ in red. Vertical lines b and c
indicate the level of section shown in the coronal sections of the SVZ and the SGZ
respectively. Line d indicates the level at which tissue was sectioned to evaluate
myelin levels from the corpus callosum. The coronal images are half nissl-stained
sections and half schematic representations. In B, the SVZ is highlighted in blue on
the nissl side. In C, the SGZ is the dark wedge seen in the in red box on the nissl
side. (Modified from the Allen Brain Atlas, 2009).
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Figure 3. Proliferative Zones of the Adult Mouse Brain
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These regions all have mitotic cell populations. Studies have shown that CNS insults
such as penetrating or diffuse brain injuries or even ischemic events cause the number of
dividing cells found in these areas to increase significantly relative to baseline levels
(Chirumamilla, 2002; Zhang, 2001). It has even been documented that the SVZ shows
evidence of increased numbers and proliferation of OPCs in human multiple sclerosis
patients (Nait-Oumesmar et al., 2007). This understandable response to most insults
suggests that the cuprizone model would also elevate the numbers of these cells, but the
hypothesis being tested here predicts that cuprizone may suppress the expected proliferative
response to demyelination.
1.3 Multiple Sclerosis and Myelin Diseases:
Myelin diseases are an unfortunately common cause of neurological deficits. Myelin
diseases can be dysmyelinating conditions in which myelin is never formed fully or correctly
in development, or they may be demyelinating diseases that cause the disruption or
elimination of previously healthy myelin (Powers, 2004). Demyelinating disorders are the
subject of this discussion; in the spectrum of these myelin disorders, multiple sclerosis is the
most prevalent. Estimates indicate that 400,000 individuals live with MS in the United States
and that there may be as many as 2.5 million people suffering from MS worldwide (Who
Gets MS, 2009).
Multiple sclerosis is a chronic demyelinating condition afflicting the CNS. In MS,
lymphocytes attack the myelin, demyelinating bundles of axons (Compston, 2008). Loss of
myelin and the concomitant axon damage lead to inconsistent, slow nerve conduction (Irvine
and Blakemore, 2008). Once an axon is demyelinated, remyelination can be slow, incomplete,
temporary or non-existent, leading to severe and long-term deficits (Compston, 2008).
Demyelinating diseases, especially MS, are marked by the presence of sclerotic plaques
throughout the CNS, hence the name multiple sclerosis. These plaques are the final result of
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the processes of inflammation, demyelination/remyelination, oligodendrocyte death, and
astrocyte reactivity (Raine, 1997).
Since plaques can form all over the brain and spinal cord, there is a very wide range of
neurologically based symptoms. Individuals are uniquely affected by MS, and so the set of
symptoms can vary significantly from one person to another. Some of the more common
symptoms that are frequently seen with MS are: cognitive impairment, changes in affect, loss
or impairment of vision, clumsiness and poor balance, tremors, vertigo, sexual dysfunction,
weakness, and pain (Whitaker and Mitchell, 1997).
In addition to a wide range of symptoms, MS can present with different courses of
progression, and in 1996, an international survey defined four prominent categories:
progressive relapsing, secondary progressive, primary progressive, and relapsing-remitting
(Lublin and Reingold, 1997). The most common course the disease takes, about 85% of
cases, is the relapsing remitting form in which patients suffer from acute attacks of declining
neurological function, relapse, followed shortly by sometimes full recovery, remission, with
relatively little progression between episodes (What Is Multiple Sclerosis, 2009). The
diversity of courses the disease can follow hints at the elusiveness of the etiology of MS.
The cause of MS remains unclear, even in the face of significant research efforts. It
is clear, however, that both environmental factors and genetic susceptibility lead to MS.
There are distinct trends in MS cases around the world that speak to a geographical and
possibly ethnic/racial/genetic influence. Tropical areas have a very low incidence of the
disease while MS has a higher occurrence in Europe and Canada. (Mathews, 1993) At the
same time, there is a twenty percent inheritance rate within families, strong enough to
implicate genetics (Compston, 2008). Typically, MS occurs in non-tropical people between
late childhood and early middle age and it occurs preferentially in women (Mathews, 1993).
With an estimated 2.5 million cases of multiple sclerosis around the world, it is
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reasonable to say that it is a problem that demands substantial research. The majority of MS
patients have the relapsing-remitting form, and even the other types often evolve from a
relapsing-remitting pattern (Who Gets MS, 2009). Each relapse, each debilitating attack,
results from the demyelination of important tracts in the CNS. The fact that there is recovery
or improvement of lost functions indicates that there is also remyelination (Raine, 1997).
This has been confirmed with MRI and post-mortem histology (Raine, 1997). Therefore, in
studying multiple sclerosis, it is as important to investigate remyelination as demyelination.
1.4 Demyelination Models:
Since MS is such a prevalent neurological disorder, several animal models have been
developed to facilitate research into the nature and treatment of MS as well as other myelin
disorders. Miller et al. outline three main types of demyelination/remyelination model:
autoimmune, virus-induced, and toxin induced (Miller et al, 1996). The common autoimmune
model is experimental autoimmune encephalomyelitis (EAE). While there are others, the most
frequently used virus-induced models are mouse hepatitis virus (MHV) and Theiler’s murine
encephalomyelitis virus (TMEV). Toxins commonly used to study myelin disorders are
ethidium bromide, lysolecithin, and cuprizone (Miller et al., 1996).
1.41 Experimental Autoimmune Encephalomyelitis:
Experimental autoimmune (sometimes allergic) encephalomyelitis is a disease in
which the T-cell mediated immune response is targeted to myelin specific antigens (Martin et
al., 1992). Acute and chronic forms of EAE cause variable demyelination. Chronic EAE can
be characterized by a relapsing and remitting time course (Raine et al, 1988). EAE is used to
study inflammatory demyelination and spontaneous demyelination and remyelination. Its use
has lead to immune-based MS therapies (Miller, 1996). The inconsistent and unpredictable
demyelination seen with EAE hinders its usefulness as a model. Also, the involvement of the
immune system adds a complicating layer to the interpretation of myelination events resulting
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from EAE (Matsushima and Morell, 2001).

1.42 Virus-Induced Models
There are several viruses that cause demyelination in animals. In mice, mouse
hepatitis virus, (MHV), Theiler’s murine encephalomyelitis virus, (TMEV), herpes simplex
virus, vesicular stomatitis virus, and Semliki forest virus have all been used to study
demyelination (Miller, 1996). While viruses have been associated with demyelination events
in humans, no virus is known to be linked to MS (Cook et al., 1995). Still, TMEV and MHV
are commonly used as remyelination models.
Though it is usually associated with the liver, as the name suggests, some strains of
mouse hepatitis virus infect the CNS and induce demyelination. MHV is commonly chosen
for studies involving the immune response to infection and demyelination in the CNS
(Matthews et al., 2002). Similarly, Theiler’s murine encephalomyelitis virus is used, like
MHV and EAE, to study the immune response to demyelination. TMEV is an unusual, and
useful, virus because it causes chronic infection. The myelin disrupting effects of infection
start early (in susceptible strains) and can fall into a relapsing-remitting pattern. (Dal Canto, et
al. 1995).
1.43 Toxin-induced models
Unlike the above model systems in which demyelination is caused by the immune
system, the toxin-induced models do not depend on the inflammatory response of the
immune system for demyelination. Ethidium bromide, lysolecithin and cuprizone are
compounds widely known and studied for inducing demyelination. The toxins act directly on
myelin or oligodendrocytes (Miller, 1996).
Injection of lysolecithin very quickly achieves local demyelination, acting in as little
as 30 minutes post-injection. The myelin sheath is directly destroyed by lysolecithin,
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attracting an inflammatory macrophage response. Remyelination is spontaneous and begins
when the myelin debris is cleared and finishes in a matter of weeks. (Hall, 1972).
Alternatively, ethidium bromide and cuprizone induce demyelination by killing
oligodendrocytes. Like lysolecithin, local injection of ethidium bromide causes short-lived
demyelination followed by spontaneous remyelination (Yajima, and Suzuki 1979). Unlike
lysolecithin and ethidium bromide, cuprizone is administered via ingestion and induces a
predictable demyelination schedule over several weeks. Remyelination ensues promptly upon
discontinuation of cuprizone treatment (Blakemore, 1973). In toxin-induced models of
demyelination, remyelination is usually quick and effective, except with long-term, severalmonth, administration of cuprizone, after which remyelination is often slow and incomplete
(Matsushima and Morell, 2001). Because demyelination is not mediated by the immune
system in these models, toxins are used to study the glial aspects of demyelination and
remyelination without the complicating factors of lymphocytes and a breached blood brain
barrier (Blakemore and Franklin, 1991; Ludwin, 1988).
1.5 The Cuprizone Model
Cuprizone (bis-cyclohexanone-oxaldihydrazone) is a copper chelator that is well
established for use as a toxic model of demyelination and remyelination. Cuprizone is used in
chemistry for its chelating properties, and the myelin pathologies seen in cuprizone toxicity
are assumed to be the result of this action, though this remains unproven (Matsushima and
Morell, 2001). Irrespective of its mechanism, Oligodendrocytes are thought to be the only
CNS cells susceptible to cuprizone (Blakemore, 1973; Komoly et al 1987). In addition to
demyelination, feeding an animal cuprizone can cause spongiform encephalopathy,
hydrocephalus, formation of megamitochondria in the liver, and changes in the activity of
copper-dependent enzymes such as cytochrome oxidase. Chelating copper to cuprizone prior
to administration prevents these pathologies, which suggests that it is this property that is
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responsible for the action of cuprizone (Matsushima and Morell, 2001). The question cannot
be considered answered however, because treating cuprizone-intoxicated animals with excess
copper does not prevent or relieve the pathologies (Carlton, 1967).
Nevertheless, the fact that metabolic pathways requiring copper are disturbed by
cuprizone indicates that it may be metabolic insufficiency that leads to demyelination and
oligodendrocyte death (Komoly, 1987). This theory is widely held because the
oligodendrocyte has a high metabolic demand as it maintains the relatively vast expanses of
membrane contained in its branches and their sheets of myelin (Matsushima and Morell,
2001). Beyond this, it is not known why oligodendrocytes are so prominently susceptible to
cuprizone. It is from the notion that oligodendrocytes are especially affected by the metabolic
disruption from cuprizone toxicity that the hypothesis tested here, that OPCs may also be
susceptible, arose.
Regardless of its uncertain mechanism of action, cuprizone intoxication has proven to
be a very useful means of studying demyelinating and remyelinating events. It has
advantages over autoimmune and virus-induced models because it is simpler and more
consistent. Additionally, cuprizone creates a more widespread and reliable demyelination than
other toxins. It is considered an excellent model for consistent, predictable, and quantifiable
demyelination and remyelination.
EAE and the virus models are known to produce spatially and temporally
unpredictable lesions. This inconsistency makes quantification and comparison across
individuals difficult (Matsushima and Morell, 2001). Cuprizone is free of this problem;
administration of cuprizone by ingestion consistently induces extensive demyelination in the
corpus callosum and the superior cerebellar peduncles, making comparisons among animals
more direct and meaningful (Ludwin, 1978). Another advantage cuprizone has over the
immune models is that it creates a much simpler system with fewer variables, perhaps since
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the blood brain barrier remains intact (Bakker and Ludwin, 1987). The immune involvement
associated with EAE, MHV, and TMEV, while very useful in its own right, clouds the glial
events of demyelination and remyelination with inflammatory compounds, cytokines,
antibodies, and lymphocytes that may have their own effects on the processes being studied
(Matsushima and Morell, 2001).
In addition, cuprizone intoxication can be used to cause a predictable course of
demyelination over time, with a consistent remyelination following recovery with a cuprizonefree diet (Blakemore, 1973; Mason et al., 2001). Cuprizone can also be used to study chronic
lesions that struggle to remyelinate (Mason, 2004). Lysolecithin and other toxic models of
demyelination are very limited in this respect. These models all have their advantages though.
In fact, the things highlighted as flaws in some contexts may be the very reasons why
investigators with slightly different specific aims may prefer them to cuprizone, but for
simply studying the events involved in the destruction and replacement of myelin, cuprizone
historically stands out as the model of choice. Because of this, the cuprizone model has been
frequently used to study oligodendrocyte progenitor cells, therapeutic approaches to
remyelination, the effects of demyelination on axons, and the characterization of
demyelination, with substantial results. (Nait-Oumesmar, 1999; Blakemore and Irvine 2008;
Irvine and Blakemore 2008; Ludwin, 1988).
1.51 The Cuprizone Model in C57BL/6 Mice
The present study was conducted using cuprizone toxicity in C57BL/6 mice. This
strain is a good choice because it offers the potential for gene function studies, but there are
many other reasons for choosing this strain. Cuprizone toxicity has been well-studied in
C57BL/6 mice ranging from weanling to aged, and with various doses and durations of
treatment (Matsushima and Morell, 2001). These studies provided the information for
choosing an age, dose and time course for the present work.
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A dose of 0.2% cuprizone in mice causes demyelination without unnecessary sideeffects such as dangerous weight loss. Higher doses that have been used in past studies,
such as 0.5 and 0.6% cuprizone have unreasonably high rates of mortality and complications
(Matsushima and Morell, 2001). Corresponding with cuprizone toxicity in other animals, the
resulting demyelination is extensive and consistent in the CC and superior cerebellar
peduncle (Ludwin, 1978). The timeline for demyelination is also consistent. Demyelination
begins within the first week of exposure and progresses until major losses of myelin are seen
in the 4th week. Removal from cuprizone in the fifth week allows a substantial remyelination
of the damaged tracts by the 8th week (Mason et al., 2000).
Since it is used to study remyelination, the response of the OPC populations to the
cuprizone model is a pertinent line of research. The study presented in this thesis does just
that. Oligodendrocytes are especially sensitive to the toxic effects of cuprizone. If this is
because the energy required to maintain a mature oligodendrocyte is not available due to the
copper chelating effects on the mitochondria, then progenitor populations, which should have
a high demand for energy as well, may also be highly susceptible. If oligodendrocytes are
selectively killed because of some particular aspect of their biochemical character, then
perhaps it is also true that the cells oligodendrocytes are derived from will have the same
inherent susceptibility. With these ideas as a foundation, this study was designed to
investigate the cuprizone toxicity model for its effects on the proliferative cells in the SVZ and
SGZ.
In order to uniquely investigate proliferating cells, they must be able to be identified.
Bromodeoxyuridine (BrdU) was chosen for identifying the proliferative cells in the SVZ and
SGZ. BrdU is a thymidine analog that competes with thymidine during DNA synthesis. As a
result, cells that undergo mitosis in the presence of BrdU incorporate it. These cells can then
be labeled immunohistochemically (Miller and Nowakowski, 1988). BrdU incorporation and
immunocytochemical identification of dividing cells form the basis for the current study.

2
Using Immunohistochemistry to Evaluate the Effects of the Cuprizone Model on the
Proliferative Cell Populations of the Adult Mouse

In order to test the response of oligodendrocyte progenitors (OPCs) residing in the
SVZ and SGZ to cuprizone over time, test groups of male C57/BL6 mice (The Jackson
Laboratory) were established according to dose and time point. Both the doses and the
time points were chosen on the basis of previous work showing the severity and course of
demyelination and its repair in the cuprizone model (Mason et al., 2001). Doses of 0.2%,
and 0.3% cuprizone were tested at 1 (3 animals at 0.2%; 5 animals at 0.3%), 3 (3 animals
at each dose), or 5 weeks of treatment (3 animals at each dose), or 8 weeks with a 3-week
recovery after a 5-week treatment (3 animals at 0.2%; 2 animals at 0.3%). Control animals
were established at 0 (4 animals) and 8 weeks (3 animals) on ground chow without
cuprizone (Table 1). Additionally, to evaluate the effectiveness of the demyelinating
model, animals were also treated in order to evaluate the extent of demyelination in 1µm
and 90 nm sections.
2.1 Cuprizone Treatment
The mice were allowed 1 week to acclimate to the AAALAC accredited Virginia
Commonwealth University Division Animal Resources room before beginning the
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Table 1. Numbers of Animals in Each Treatment Paradigm
Ten test groups of male C57/BL6 mice 6 weeks old were established: 2 control
groups, and 8 experimental groups. The control animals were given no cuprizone,
but ground chow, for either 0 or 8 weeks. Experimental animals were fed ground
chow containing either 0.2 or 0.3% cuprizone. These animals were divided into 1,
3, 5, and 8 week groups. The 8-week animals were fed chow without cuprizone for
the final 3weeks.
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4

0

0

0
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0
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3

3

3
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3

3
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Table 1. Numbers of Animals in Each Treatment Paradigm
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treatment regimen at 6 weeks of age. The administration of cuprizone was accomplished
by mixing the neurotoxin into their food. The food was prepared by adding the appropriate
mass of cuprizone to ground rodent chow (Harlan). Homogeneity of the cuprizone mixture
was achieved by 5 minutes of vigorous shaking to prevent the mice from selectively avoid
the cuprizone. The animals were checked and fed 6 times a week. At each feeding, the
food jars (5.5cm x 6.5 cm) were refilled to their 100-g capacity. In addition, the animals
were weighed weekly to monitor for dangerous weight loss.
2.2 BrdU Injection
48 hours prior to the end of their treatment paradigm, the animals received a single
intraperitoneal injection with BrdU in order to label dividing cells. The dose chosen for the
injections was 300 mg/kg body weight. Cameron and Mckay compared many BrdU doses
and found that lower doses labeled fewer cells and higher doses did not label any more
cells (Cameron and McKay, 2001). The BrdU was dissolved in a solution of .007 M
NaOH in 0.9% (normal) saline and injected intraperitoneally (Cameron and McKay, 2001).
After the injections, the mice remain on cuprizone until they are sacrificed.
2.3 Immunohistochemical Processing for Flourescence:
2.31 Perfusion
In order to harvest brain tissue for processing, the animals were perfused and their
brains dissected. Intraperitoneal injection of Avertin (2,2,2 tribromoethanol (SigmaAldrich) in a solution of 1% tert-amyl alcohol in 1x phosphate buffered saline (PBS)) was
used to anesthetize the animals for the procedure. Once sufficiently anesthetized,
transcardiac perfusion was performed with 0.9% saline at 5ml/min. Once a perfusion was
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complete, the skull was opened and the brain removed. Immediately, the brain was frozen
by submergence in a -25°C bath of 2-methylbutane. The frozen brains were removed
from the bath and briefly stored, individually wrapped in aluminum foil, at -20°C until
sectioning. For each animal, the liver was removed and frozen in the same manner as the
brain. The livers were harvested to serve as a positive control for BrdU.
2.32 Sectioning
The brains were sectioned to allow for the microscopic evaluation of the SVZ and
SGZ. Coronal sections were cut at a thickness of 40µm using a Leica CM 1850. 3 series
of sections were collected starting at the anterior reaches of the lateral ventricles where the
white matter tracts become arcuate and proceeding to the posterior extent of the dentate
gyrus of the hippocampus. In each series, every 5th section was collected on charged
slides. For each animal, an average of 14 sections were collected for the SVZ and 8
sections for the SGZ per series.
2.33 Staining
For evaluation of BrdU, the sections were fixed in 4% paraformaldehyde for 15
minutes, washed (3 times for 5 minutes each) in 1x PBS, then soaked in 3N HCL for 30
minutes to denature nucleic acids, which makes the BrdU epitope accessible to antibodies.
Another thorough PBS wash preceded blocking the sections in a block solution of PBST
(0.4 % Triton X-100 (Sigma) in 1x PBS) containing 4% normal goat serum for 1 hour.
Upon completion of blocking, the sections were incubated overnight at 4°C with
monoclonal mouse antibody against BrdU (Dako) at a concentration of 1:200 in block
solution.
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In order to visualize the BrdU, the primary antibody was thoroughly washed off with
PBST immediately prior to incubation in a fluorescent goat anti-mouse secondary antibody
(Alexa Fluor 488) at 1:400 in block solution. After incubating at room temperature for 2
hours, the sections were washed first with PBS then with deionized water before being
coverslipped with Vectashield mounting medium (Vector Laboratories) to enhance and
preserve fluorescence. The slides were then stored at 4°C.
2.34 Quantification
The proliferative response of cells in the SVZ and the SGZ to cuprizone treatment was
evaluated by counting BrdU labeled cells in those regions with fluorescence microscopy.
Using an Olympus BX-51 at 40x, every BrdU+ cell in the animal’s right SVZ and the
ipsilateral SGZ was counted manually in each section. For objectivity and consistency, the
SVZ and SGZ were counted from the same side of the brain (right) in each section for
every animal.
2.4 Processing for Semi-thin and Thin Sections:
2.41 Perfusion and Fixation
The mice were anesthetized as above for transcardial perfusion fixation for 0.5µm
section processing. Normal saline was used to flush the animals until the perfusate ran
clear. This was followed by 5 ml/min perfusion with a fixative solution of 0.1M Millonigs
phosphate buffer (pH 7.3) containing 5% glutaraldehyde (Electron Microscopy Sciences)
and 4% paraformaldehyde (Electron Microscopy Sciences) for fixation. The mice were
perfused for 20 minutes after cessation of muscle twitches. After perfusion, the brain was
dissected and submerged in the fixative solution at 4°C for 2 weeks. Then the brain was
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soaked overnight in 0.1M cacodylate buffer (Electron Microscopy Sciences) to remove
excess aldehydes.
2.42 Tissue Processing
The whole brain was bisected mid-sagittally and the right hemisphere embedded in
agarose to be sectioned. Four (4) 500µm sections were cut coronally on a Leica VT 1000s
vibratome. Corresponding 500µm sections were selected from each brain. Each section
was then rinsed in cacodylate buffer and post-fixed in 1% osmium tetroxide (Electron
Microscopy Sciences) for 1 hour while being constantly agitated. The post-fix was
followed by 3 rinses in cacodylate buffer then dehydration in serial dilutions from 30% to
100% ethanol at 4°C. Each section was incubated twice for twenty minutes each in
propylene oxide and then the tissue was left overnight in a mixture of one part PolyBed
(Polysciences, Inc.) and one part propylene oxide according to the manufacturer’s protocol.
The next day, each section was embedded in fresh PolyBed resin. The resin blocks were
polymerized in an oven at 55°C for 48 hours and sectioned to 0.5µm on a Leica EM UC6
microtome.
2.43 Staining and Imaging for 0.5 µm Sections
The 0.5µm sections were stained with a toluidine blue solution. To make the
staining solution, 0.1g each of Toluidine Blue O (Fisher Scientific, Inc.), Methylene Blue
(Fisher Scientific, Inc.), and Azure II (Polysciences, Inc.) are added to 1% sodium borate
in distilled water, mixed well, and filtered. The 0.5µm sections are allowed to dry on
slides resting on a hot plate at 60°C. While on the hot plate, the slides are covered with the
toluidine blue solution for 3-5 minutes until appropriate staining is achieved. Finally the
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sections are rinsed in water, dried and coverslipped with Permount mounting medium. The
sections were examined in bright field at 100x with a Nikon Eclipse 800 light microscope.
Images were captured from this scope with an RT sliding spot scope from Diagnostic
Instruments, Inc.
2.44 Staining and Imaging for 90nm Sections
Resin blocks are prepared as above and a PolyBed block is cut to 90nm on a Leica
EM UC6 microtome. The sections are collected on EM grids. The grid with the section is
allowed to dry before being stained. The grids are placed in a solution of 5% uranyl
acetate in 50% methanol for several minutes, rinsed 3 times in distilled water, carefully
blotted dry, and placed in filtered Reynold’s Lead Citrate solution. After several minutes in
Reynold’s the stained sections are allowed to dry. These 90nm sections were analyzed
using a JEM1230 transmission electron microscope (JEOL Ltd.) equipped with a Gatan
Ultrascan CCD camera (Gatan, Inc.).
2.45 Quantification
Saggital images of the corpus callosum at the level of the branching of the fornix
were evaluated for myelination levels. The number of myelinated axons was counted
individually from each image.
2.5 Data Analysis
The BrdU+ cell counts were reported for each section from the rostral extent of the SVZ to
the caudalmost reaches of the SGZ. For every animal, the number of BrdU+ cells counted
in each section was averaged for the SVZ and the SGZ. These data, reported as
BrdU+cells per section, underwent statistical analysis. Each treatment group was
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compared to the control group using a Student’s t-test against the null hypothesis that
experimental values do not differ from control values. Also, the myelinated axon counts
were analyzed. The counts were reported as the number of myelinated axons per field.
The data for each treatment were compared to the control levels using t-tests.

3
The Cuprizone Model Affects CNS Cells Other Than Mature Oligodendrocytes

3.1 Demyelination and Remyelination of the Corpus Callosum
This research focuses on the cuprizone model for toxic demyelination. Previous
work from many labs has shown that cuprizone causes consistent and substantial
demyelination in the major white matter tracts of the CNS. Using this toxin in C57BL6
mice should therefore yield a decrease in myelin wrapped axons in the corpus callosum.
High magnification (1000x) inspection of 1 µm mid-sagittal sections of the corpus
callosum at the level of the fornix (see line d in Figure 3) shows that the cuprizone dosing
regimens of 0.2 and 0.3% do cause obvious demyelination relative to control after 5 weeks
(Figure 4). Counts of myelinated axons confirm the apparent demyelination in the corpus
callosum (Figure 4). 5 weeks of 0.3% cuprizone treatment is characterized by a 65% loss
of myelinated axons from the control level of 3099 axons/field to 1087 axons/field. The
images and the counts are also consistent with a remyelination event after 3 weeks without
cuprizone. There is a 117% increase from 1087 cells/field at 5 weeks to 2360 cells/field at
8 weeks, restoring the corpus callosum to 76% of control levels (Figure 4). Confirmation
of demyelination was achieved by inspection at 8000x with electron microscopy
(Figure 5).
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Figure 4. Cuprizone-induced Demyelination in the Corpus Callosum
Myelinated axons are counted in mid-sagittal sections of the corpus callosum at the
level of the fornix, as illustrated by line d in Figure 3A. Control animals show high,
consistent, and evenly distributed myelin levels, A. Five weeks on 0.2% cuprizone
causes demyelination and the number of myelinated axons is greatly reduced, B. 3
weeks without cuprizone following a 5-week demyelinating cuprizone regimen
allows remyelination as seen in C . The bar graph, D, illustrates that the number of
myelinated axons per field decreases to 35% of control with cuprizone. When
cuprizone is removed from the diet for three weeks the myelinated axon count
recovers to 76% of control levels. (Scale bar = 5 µm)
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Figure 4. Cuprizone-Induced Demyelination in the Corpus Callosum
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Figure 5. Electron Micrographs of Corpus Callosum
The apparent demyelination seen in the light microscopy images from which the
myelinated axon counts were taken (Figure 4A-C) was confirmed with electron
microscopy at 8000x. Image A shows control levels of myelination. EM shows a
demyelination at 5 weeks on cuprizone, B, and a rise in myelinated axons after 3
weeks of recovery, C. (Scale bar = 1 µm)
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Figure 5. Electron Micrographs of Corpus Callosum

34
3.2 BrdU Immunohistochemistry:
3.21 Cuprizone affects BrdU Incorporation in the SVZ
Immunohistochemistry for BrdU allows the visualization of cells that have undergone
mitosis after injection of the thymidine analog. BrdU was injected 48 hours prior to
sacrificing the animals to identify populations of dividing cells. The use of a fluorescently
tagged antibody to BrdU shows that cuprizone dramatically decreases the number of
proliferative cells in the SVZ and SGZ.
The control animals have an average of 117 BrdU+ cells per SVZ section. In the control,
the labeled cells are well distributed and fill the SVZ. For both 0.2 and 0.3% doses in the
SVZ, the number of BrdU+ cells drastically declines to less than 10% of control after just 1
week of cuprizone treatment (Figures 6,7). This result is significant with a p-value <5.0E6

relative to control. All p-values here compare experimental values to control values in a

Student’s t-test. Over the course of several weeks, the labeled population grows, showing
more BrdU+ cells. After 3 weeks of cuprizone, 0.2%-treated animals exhibit an increase to
65% of control (p<0.01) while 0.3% animals only recover to 19% of control (p<5.0E-5). At
5 weeks, the point of the most significant demyelination, the number of BrdU+ cells in the
SVZ has returned to 88% of control levels at 0.2% cuprizone, and 63% at 0.3% (p<0.05).
Yet, after 3 weeks of recuperation from cuprizone, the animals at both doses fail to recover
entirely to control numbers with 0.2% cuprizone at only 61% of control and 0.3% reaching
69% (p<0.005). Both cuprizone doses induce the same trend, a drastic drop in BrdU+ cells
followed by a slow and incomplete comeback; the difference is that the SVZ in 0.3%
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treated animals remains suppressed longer, but ultimately 0.2% and 0.3% return to about
the same level. (Figure 7).
3.22 Cuprizone affects BrdU Incorporation in the SGZ
BrdU incorporation was also investigated in the SGZ with cuprizone intoxication.
The SGZ exhibits a response similar to that seen in the SVZ. The SGZ response to
cuprizone is shown in Figure 8. As with the SVZ, BrdU labeling rapidly decreases to
<10% of control (p<0.005) in the first week of cuprizone treatment for both doses. At 3
weeks, 0.2% animals recover to a level not statistically significantly different from control
(p=0.32) and even 0.3% animals rise to 43% of control (p<0.05). After this increase the
number of labeled cells at both treatments drops again by 5 weeks. Even after three weeks
off of cuprizone, both doses remain below 30% of control. This is in contrast with the
modest recovery seen in the SVZ.
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Figure 6. BrdU+ Cell Counts Fall Drastically After Only 1 Week on Cuprizone and
Recover After 3 Weeks Without Cuprizone
Under control conditions, the SVZ is well populated with BrdU + cells distributed
throughout the zone, A. After 1 week of 0.3% cuprizone, B, the SVZ is nearly
depleted of BrdU+ cells. C shows a significant recovery in the number of labeled
cells 3 weeks after removal from a 5-week 0.3% cuprizone diet. D shows a nisslstained section through the lateral ventricle at the same level as A, B, and C to
serve as a reference. scale bar = 100µm.
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Figure 6. BrdU+ Cell Counts Fall Drastically After Only 1 Week on Cuprizone and
Recover After 3 Weeks Without Cuprizone
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Figure 7. The Number of BrdU+ Cells/Section in the SVZ Over Time for Each Dose
Control animals average 117 cells/section. 1 week of cuprizone causes a steep
decline to 9 cells/section for 0.2% (p<5.0E-6) and 6 cells/section for 0.3% (p<5.0E6) after three weeks on cuprizone, the levels are 76 cells/section for 0.2% (p<0.01)
and 21 cells/section for 0.3% (p<5.0E-3). 5 weeks sees the highest levels for 0.2%
at 104 cells per section (p<0.05), but 0.3% only reaches 71 cells/section at this
point (p<0.05) After three weeks without cuprizone, 0.2% animals show a decrease
to 72 cells/section (p<5.0E-3) while there is no significant change between 5 and 8
weeks for 0.3%
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Figure 7. The Number of BrdU+ Cells/Section in the SVZ Over Time for Each Dose
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Figure 8. The Number of BrdU+ cells/section in the SGZ Over Time for Each Dose
Cuprizone
In the SGZ, control animals average 7 cells/section. Like in the SVZ ,1 week of
cuprizone also causes a steep decline in the SGZ to <1 cell/section for 0.3%
(p<1.0E-3) and <2 cells/section for 0.2%. After three weeks on cuprizone, the
count is 3.5 cells/section for 0.3% animals (p<0.05), but has increased to 6
cells/section for the lower dose. 5-week and 8-week cell counts dwindle again to
3.2 and 1.4 cells/section respectively for 0.3%(p<0.01). Similar counts are seen
with 0.2% at these later time points.
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Figure 8. The Number of BrdU+ cells/section in the SGZ Over Time for Each Dose
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4
Cuprizone’s Effect on Cells in the SVZ and SGZ brings New Insights to the Use of
the Model

The novel findings presented here may have significant implications for the use of the
cuprizone model. The cuprizone regimen followed does induce significant demyelination
followed by remyelination, but it seems that cuprizone may have broader effects in the brain
than previously believed. The BrdU data show conclusively that cuprizone impacts the
dividing cells in the generative zones of the brain. This is the first observation that
cuprizone’s cellular effects in the adult brain are not limited to mature oligodendrocytes.
This new finding has substantial repercussions on the interpretation of studies using the
cuprizone model.
4.1 Demyelination in the Cuprizone Model
The clear loss and eventual recovery of myelinated axons as seen in 1µm sections
stained with toluidine blue confirms the demyelinating/remyelinating action of the cuprizone
model. The demyelination and subsequent remyelination trends observed in the C57/BL6
mice in this study are also in accord with the established timeline for the model (Mason et al.,
2001). The cuprizone model did cause consistent, predictable demyelination in the current
study. As such, the cuprizone toxicity model is a good one for causing myelin disruption and
loss. However, the results of the BrdU experiments have implications that may restrict the
utility of this popular model.
4.2 Trends in the BrdU labeling of the SVZ and SGZ
It would normally be expected that the introduction of a toxin and the associated
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demyelination would cause an increase in the number and proliferation of progenitors in the
SVZ and SGZ that may be concurrent with demyelination. This is because most CNS
insults, including demyelination, induce a well documented proliferation of cells in these areas
(Chirumamilla, 2002; Nait-Oumesmar et al., 2007; Zhang et al., 2001). However, this study
found that the response to cuprizone in the SVZ as evidenced by BrdU
immunohistochemistry occurs very shortly after cuprizone administration. Furthermore, in
both 0.2% and 0.3% conditions, the SVZ response is an abrupt, steep decline in the number
of cells incorporating BrdU. After the drop seen in the first week, BrdU+ cells slowly
become more numerous. The number of the BrdU+ cells in the SVZ reaches the highest
non-control levels after 5 weeks on cuprizone, and the population fails to recover further
when the insulting cuprizone is removed from the diet.
While the trends for the two dosages are very similar they are not the same. In the
first week, the lower dose induces almost the same percent decrease in labeled cells as does
0.3% cuprizone; average BrdU counts at both doses were within 3 cells of one another, and
both were less than 10% of control levels. At 3 weeks though, 0.2% cuprizone allows some
recovery while the 0.3% treatment continues to suppress the number of labeled cells. After 2
more weeks, the 0.2% BrdU+ cell count reaches its highest point at 5 weeks, and then the
number declines slightly after 3 weeks without cuprizone. On the other hand, BrdU+ cell
counts at 0.3% begin to rise more dramatically after the 3rd week, but do not change
significantly after the 5th week.
4.21 BrdU+ Cell Counts Initially Decrease Upon Cuprizone Administration
At each dose, anti-BrdU labeling of cells in both zones examined shows a drastic
decline in BrdU incorporation. The number of cells that label positive for BrdU after a single
injection depends on the number of dividing cells and the rate of division, so any change in
the number of BrdU+ cells could be attributed to several things. The decrease seen in BrdU
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labeling does not specify exactly what cellular events are occurring in the SVZ and the SGZ,
but it clearly shows that the cells in these areas do respond to cuprizone. It is possible that a
large percentage of the cells labeled in the control condition could be dying because of the
cuprizone. Alternatively, the toxin may induce the cells to halt their cell cycle or at least to
reduce their rate of reproduction. Another possibility is that cells are migrating out of the
counted areas.
The effect of cuprizone on mature oligodendrocytes is commonly attributed to
metabolic insufficiencies due to the copper chelating properties of the toxin (Matsushima and
Morell, 2001). Cuprizone is known to interfere with copper-dependent enzymes that are
necessary for ATP production (Suzuki, 1969). This aspect of cuprizone intoxication, which
is thought to kill mature oligodendrocytes, may be causing the trends revealed by the data
obtained in this study.
The immature, dividing, cells of the SVZ and SGZ may be very vulnerable to
metabolic insults. A dividing cell must expend large amounts of energy to copy its genome,
and to make enough proteins, organelles, and membrane to serve 2 daughter cells. In addition
to these things, new cells grow and sometimes migrate. These all serve to create a high
demand for ATP, which may not be met in the presence of cuprizone. Cells may die in
response to a cuprizone-induced decrease in ATP production, or the cells may respond by
decreasing their demand for energy, stopping or slowing cell division processes and entering
G0, as is commonly seen in cells and organisms which do have the ability to become
quiescent when the environment becomes inhospitable (Cook et al., 2000).
Cell death, necrotic or apoptotic, could explain the observed change in BrdU+ cell
counts. The death of cells prior to the BrdU injection clearly prevents incorporation of the
marker, but cells dying after the BrdU injection might not be labeled either. These cells may
already have the thymidine analog in their DNA. If this were the case though, the cells would
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very likely still not label BrdU+ because necrotic and apoptotic processes result in the
disassembly of the nucleus and digestion of the cell’s DNA (Nagata, 2000). The fragmented
DNA of dead cells would therefore not be accounted for in counts of BrdU+ nuclei. Only if
the cell death occurs just prior to perfusion, before the DNA degrades, might BrdU still label
cells that have died. Unfortunately, the possibility of cell death adds a complicating factor;
BrdU has also been reported as an effective marker for DNA damage and apoptosis (Li,
1995). While this fact may complicate the interpretation of the results of the current study,
one may also deduce that the loss of BrdU positive cells should not correlate with cell death.
Another possible explanation for the drastic reduction in BrdU+ cells is a change in
mitotic activity. Before a eukaryotic cell can divide, it must make a second copy of the DNA
contained in its nucleus. This replication of DNA occurs in the S, or synthesis, phase of the
cell cycle. It is because it competes with thymidine in DNA replication that BrdU acts as a
cell proliferation marker (Miller and Nowakowski, 1988). Perhaps the cells that are actively
reproducing under control conditions simply fail to initiate the cell cycle or halt their progress
through the cycle at some point.
Clearly, BrdU will not label a cell that is no longer actively progressing through the
cell cycle, but a cell that has only slowed down its division rate may also be exempt from
incorporating BrdU. This is because BrdU only remains available in the brain for as little as
2 hours post injection (Cameron and McKay, 2001). Given the limited temporal availability
of BrdU, only cells that happen to enter S phase during the critical period can incorporate the
compound. The slower the division cycle, the less probable it is that a given cell is in S phase
while BrdU is available. Because of this, merely slowing the rate of advancement through the
cell cycle from 6 hours to 18 hours would have a dramatic effect on the number of labeled
cells.
Alternatively, there is another situation that may account for the loss of BrdU+ cells,
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though it may not be a direct result of cuprizone on the dividing cells. Migration of cells out
of the examined areas would explain the observations made after 1 week on cuprizone.
Migration is not a logical consequence of cuprizone on the OPCs or any other cells in the
SVZ, but cuprizone may be indirectly triggering the migration of cells by causing other cell
types to release signaling molecules. While migration could cause a decrease in BrdU+ cell
counts, the large percentage decrease and the short time frame are not indicative of a
migration event. Also, were the cells to migrate, cells outside the areas of interest would label
BrdU+ and a qualitative observation of the nearby brain regions revealed that very few cells
outside the SVZ and SGZ took up BrdU at 1 week.
There are several possible explanations for the initial BrdU+ cell count reduction after
1 week of cuprizone administration. The mechanism of BrdU labeling itself does not
necessarily favor one of these explanations over the others. Although, the facts that BrdU can
label apoptotic cells and no BrdU+ cells were seen outside the proliferative zones argue
against apoptosis and migration. Even without confidently knowing why the BrdU counts
decrease, it is undeniable, given the strength of the statistical significance, that cuprizone has a
drastic effect on the cell populations under investigation in the SVZ and the SGZ.
4.22 BrdU+ Cell Counts Trend Back Toward Control Levels after Initial Decrease
After the initial decline in BrdU+ cells, the labeled cell population in the SVZ begins
to grow, even in the presence of cuprizone. The reasons for this are not clear, but there are
several possible explanations for the trends seen at each time point. The explanations for the
initial decreases have already been discussed, but they do not account for the trends seen at 3,
5, and 8 weeks. As mentioned previously, the number of BrdU+ cells after a single injection
depends on the number of dividing cells and the rate of division, so, for any time point after
the initial decrease, changes in the number of BrdU+ cells could be attributed to several
things. Increases may be due to cells that were largely unaffected by cuprizone toxicity
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reproducing or to cells that had arrested or slowed their cell cycles increasing their
proliferation rates. Also, cessation of an apoptotic response or decreased migration could
explain the resurgence in BrdU levels in the SVZ. Decreases may be attributed, as with the
decline seen at 1 week, to cell death, cell cycle arrest or retardation, or migration.
At 3 weeks, the number of labeled cells counted increases from 1 week for both
treatments, but the increase is much greater for 0.2% cuprizone. Mason et al. have shown
that there is oligodendrocyte apoptosis after 3 weeks of cuprizone treatment (Mason, 2000).
The death of oligodendrocytes and the early stages of demyelination may chemically trigger a
proliferative response in the immature cells. The influence of these triggering factors may
cause the cells that have survived cuprizone thus far to increase their division rate, causing
more of them to take up BrdU. These signals may not be strong enough to significantly
overcome the toxic effects of cuprizone at the 0.3% dosage, explaining the differences in cell
counts at this time point.
At 5 weeks, the population of BrdU+ cells increases still further from 3 weeks and
reaches its highest point in the 0.2% animals. The 0.3 % animals also exhibit a strong
increase from 3 weeks to 5 weeks. By this time, there has been apoptosis in the
oligodendrocyte populations and the major tracts are largely demyelinated (Mason, 2000).
The dying oligodendrocytes and the microglia clearing myelin debris could be very strongly
signaling for the germinal zones to increase their proliferation rates. With such extensive
oligodendrocyte death and demyelination, the signals could be strong enough to overcome the
effects of even 0.3% cuprizone, accounting for the increases seen in both treatment groups at
5 weeks.
The cuprizone regimen ends at 5 weeks, and the animals were allowed to survive for 3
more weeks without the neurotoxin. The BrdU+ cell counts do not increase dramatically
without cuprizone. In fact, the 0.2% animals experience a significant decrease in the number
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of labeled cells. This trend was unexpected, but might not be that surprising. At 8 weeks,
remyelination is substantial, and there are no major apoptotic events. After the 5-week time
point, the signals for increased proliferation should dwindle. It may be expected that the
germinal populations would return to control levels with no cuprizone and no unusual
signaling factors. Instead, the level decreases at 0.2% (p<0.05) and the increase seen at 0.3%
is not statistically significant (p=0.32).
A population of dividing cells in an organism that is beyond developmental stages
would not be expected to increase under normal conditions. The cells in such a population
should reproduce at a rate equal to the rate at which cells are lost. If the populations that take
up BrdU under control conditions follow such a paradigm, then it is not so unusual that there
is not a full recovery to control levels when cuprizone is withheld from the diet. Without
cuprizone, the cellular environment could begin to return to normal. In this case, it would be
expected that the population would not show an increase from 5 weeks. Even the decrease
seen at 0.2% may be explained; the cells were dividing at an elevated rate, even with
cuprizone, because of the molecular cues from the loss of oligodendrocytes and myelin.
Removing cuprizone eliminates these cues and the rate of cell division returns to normal,
decreasing from the elevated rate and accounting for the decrease in BrdU labeled cells seen
at 8 weeks.
Migration of cells away from the SVZ could also be responsible for the trend seen at
the end of the treatment paradigm. At 5 weeks, and during the subsequent recovery weeks,
remyelination is an ongoing process; the oligodendrocytes killed by cuprizone must be
replaced for there to be new myelin, so OPCs could be migrating from the SVZ to replace the
oligodendrocytes directly, or moving in to replace the cells that do replace the dead
oligodendrocytes. Migration out of the SVZ would account for the apparent failure of the
cells to recover from cuprizone. If cells remove themselves from the SVZ via migration at a
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rate similar to that of proliferation, there would be no increase. And if the cells migrate even
faster, there may be a decrease, as is seen at 0.2% cuprizone. It should be noted that, while
migration is not easily ruled out as an explanation for the trends from 5-8 weeks, it is not
likely to be the explanation for the initial decrease seen in week 1. This is because many cell
types could be taking up BrdU, and it is improbable that such a large majority of these cells
would depopulate the area so soon, especially since migration requires significant energy
expenditure. Also, if the cells migrated there should be BrdU+ cells outside the SVZ and
SGZ at 1 week, and there are not.
4.3 Response of the SGZ to Cuprizone
Most of the discussion thus far pertains to the SVZ, but the BrdU levels observed in
the SGZ suggest that the germinal zone in the hippocampus is also sensitive to cuprizone.
The same explanations used for the initial SVZ response may largely account for the
observations made in the SGZ, but, in vivo, the cells in the SGZ are thought to be exclusively
neuronally-fated stem cells (Kempermann et al., 1997; Palmer et al., 1997). In culture, they
have been molecularly guided toward differentiating into glia (Palmer et al, 1997). However,
in the first week of cuprizone treatment, there should be no signals directing these cells into
the oligodendrocyte lineage. Yet these cells do show the same drastic decrease in BrdU
labeling that is seen in the SVZ. This indicates that even dividing cells without glial-restricted
fates are affected by cuprizone. The BrdU+ cell counts in the SGZ do not recover to any
great extent at 5 or 8 weeks as seen in the SVZ. Since the SGZ cells are not typically glial
precursors, they may be expected not to respond to signals from myelin disruption and
oligodendrocyte death. Perhaps this is why BrdU counts in the SGZ do not recover while the
SVZ does show some recovery.
This conclusion that mitotically active cells that are not in the oligodendrocyte lineage
suffer from cuprizone toxicity also helps to explain the size of the decrease initially seen in
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the SVZ. Alvarez-Buylla’s lab showed that only 15% of the cells normally present in the
SVZ are likely to be glial precursors (Doetsch et al., 1997). If cuprizone were only toxic to
these cells, then the change in BrdU+ cell numbers should not be as drastic as 90% of
control. However, if cuprizone were toxic to more generic dividing cells, such a large
decrease would be expected.
4.4 These Findings Confirm Hypothesized OPC Susceptibility to Cuprizone
The hypothesis tested by these experiments was that the oligodendrocyte progenitor
cells should be susceptible to the effects of cuprizone. This hypothesis was proposed on the
basis of the potential mechanism of action of cuprizone and the hypothetical metabolic
activity of OPCs. Also, if there were anything in the oligodendrocyte lineage that makes them
susceptible for non-metabolic reasons, then OPCs may share that susceptibility. The data
presented here support this hypothesis, suggesting that, in fact, the immature cells of the SVZ
and SGZ may be more sensitive to cuprizone toxicity than mature oligodendrocytes are.
4.5 Insights in the Mechanism of Action of Cuprizone
The observation that such a large majority of the BrdU+ cells in both the SVZ and
SGZ responds to cuprizone does support the idea that OPCs are affected by cuprizone, but it
also suggests that OPCs are not the only cells in these regions that suffer from cuprizone
toxicity. There is no evidence here that early OPCs are more sensitive than other dividing cell
types in the CNS. This suggests that there is not a feature common to the oligodendrocyte
lineage that makes them susceptible to cuprizone, which leaves the default explanation that the
effects of cuprizone are due to metabolic effects.
4.6 Applications of the Cuprizone Model Considering This Result
The finding that the dividing cells of the SGZ and SVZ are susceptible to cuprizone is
not only a novel observation, but it also has significant ramifications for the uses of the
cuprizone model. These data may call into question the suitability of cuprizone toxicity as the
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model of choice for studying remyelination. Other uses of the cuprizone model may also
need to be reconsidered in light of these findings.
It is known that cells in the SVZ can differentiate into myelinating oligodendrocytes
(Menn et al., 2006). Given this, it follows that any toxin that acts on these cells may interfere
with myelination. The cuprizone model is widely used to study the processes of
demyelination and remyelination (Blakemore, 1973a; Koutsoudaki, 2009). Bearing in mind
the toxic compound’s effects on immature cells in the SVZ and the potential role of OPCs in
remyelination, results of these studies may need to be reinterpreted. Presumably,
remyelination cannot proceed in the same fashion with these immature cells responding to
cuprizone as it would were they unaffected as they have been assumed to be.
Some studies have used the cuprizone model to investigate the response of OPC
populations to demyelinating events (Raine et al., 1988; Blakemore and Franklin, 1991;
Mason et al., 2004). Therapeutic approaches using OPCs have also been tested in the
cuprizone model (Blakemore and Irvine, 2008). Considering the current data, there are
several reasons that cuprizone may be a poor choice for studies of this nature. If cuprizone
affects immature OPCs, as it appears to, then using the model to cause demyelination in
studies investigating the OPCs themselves may weaken or invalidate the results. For a study
of this nature, the OPC response should be exclusively due to demyelination, not to the toxin
causing the demyelination. Also, in vitro studies have shown that cuprizone prevents the
differentiation of adult OPCs (Cammer, 1999). Therefore, therapeutic studies that use less
immature OPCs may still have the same problem; the cells respond to the toxin, not just to the
demyelination. One may expect that OPCs would have a more robust response to
demyelination itself than is found in cuprizone studies. Another consideration regarding
cuprizone and OPC research is the increase in OPC proliferation in the SVZ associated with
MS in humans.
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The evidence presented here needs to be considered when researchers choose the
most appropriate model system for their work. Experimental aims that focus on the process
of remyelination or on OPCs responding to demyelination might exclude cuprizone as an
option. However, cuprizone is still a fine choice for demyelination because it is not immune
mediated and is very consistent. Also, these results have little impact on studies of axoglial
interactions and demyelination-induced axon damage. For many studies, cuprizone could be
a very good model, but the applicability of the model is narrowed by this observation that
cuprizone affects CNS cells other than mature oligodendrocytes
4.7 Conclusion
The cuprizone model has been popularly used to study demyelination and
remyelination for a half-century because it produces consistent results and has been thought
only to affect myelinating oligodendrocytes, sparing other CNS cell types. However, our
observations indicate that oligodendrocytes are not the only CNS cells susceptible to the toxic
effects of cuprizone. This immunohistochemical study of BrdU incorporation indicates that
populations of dividing cells in the subventricular and subgranular zones of adult mice are
very sensitive to the toxin. These results suggest that cuprizone causes cell death or cell cycle
perturbation in oligodendrocyte progenitor cells and other proliferative cell types.
This novel insight into the cuprizone model could have significant ramifications for its
applicability to future studies and for the interpretation of prior research. The results of many
experiments using this model system may be undermined or invalidated by the direct effects
of cuprizone on OPCs. Considering this new finding, future studies concerning OPCs and
remyelination should weigh alternative models carefully.
The current study of the cuprizone model is not able to provide sufficient evidence to
specifically discriminate between the possible cellular events responsible for the observed
changes in BrdU+ labeling. Further pursuit of this question by investigating additional time
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points, looking for signs of cell death, and attempting to identify the cells that take up BrdU is
in progress. Cuprizone can still be an effective model to study various aspects of
demyelination. Hopefully, this addition to the body of knowledge describing the actions of
the cuprizone model will help to explain and interpret results obtained using the model and
further the understanding of demyelination/remyelination processes and the development of
more effective therapies for myelin disorders like multiple sclerosis.
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